Abstract
Compound 2 was identified by high throughput screening as a novel PAI-1 inhibitor. Systematic optimization of the A, B, and C segments of 2 resulted in the identification of a more potent compound 39 with good oral bioavailability. The synthesis and SAR data are presented in this report.
MeSH terms
-
Animals
-
Blood Coagulation Tests
-
Drug Evaluation, Preclinical
-
Fibrinolysis / drug effects
-
Molecular Structure
-
Piperazines / chemical synthesis*
-
Piperazines / pharmacology*
-
Plasminogen Activator Inhibitor 1 / chemistry*
-
Plasminogen Activator Inhibitor 1 / metabolism
-
Rats
-
Structure-Activity Relationship
Substances
-
Piperazines
-
Plasminogen Activator Inhibitor 1